As part of the Severo Ochoa Patient and Citizen Involvement Programme, the 4th Patient Day was held on 10 April,…
news
Results of a VHIO led study show that up to 90% of chronically hypoxic patients have an EPAS1 alteration in…
Led by investigators of VHIO’s Radiomics Group, a review article published in ESMO Real-World Data and Digital Oncology—the European Society…
The results show the need for continuous monitoring of patients to detect and manage possible adverse effects occurring months and…
Co-authored by leading experts in oncology, a review article recently published in the Journal of Clinical Oncology (JCO)* provides an…
The American Association for Cancer Research (AACR) has officially announced this year’s class of Fellows of the AACR Academy. The…
Initial results of the COMPETE phase 3 clinical trial—the first study to compare targeted radioligand therapy with molecular targeted therapy…
On February 26, the second edition of the Computational Oncology Master Thesis Awards took place, organized by VHIO with the aim of…
The MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance,…
Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…
